Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 36
Filter
1.
Exp Clin Transplant ; 19(8): 842-848, 2021 08.
Article in English | MEDLINE | ID: mdl-34142940

ABSTRACT

OBJECTIVES: Histidine-tryptophan-ketoglutarate and University of Wisconsin solutions are currently used for pancreas graft preservation. Our hypothesis was whether the use of histidine-tryptophan-ketoglutarate solution is associated with worse pancreas graft survival than University of Wisconsin solution, in general and after prolonged cold ischemic time of ≥12 hours. MATERIALS AND METHODS: This retrospective study investigated the impact of static cold storage in histidine-tryptophan-ketoglutarate (n = 133) versus University of Wisconsin (n = 107) solution on outcomes of 240 pancreas transplant procedures. Patient and graft survival rates were compared after 1, 3, and 5 years in both groups. Serum lipase, amylase, and C-reactive protein levels and incidence of surgical complications were evaluated at postoperative week 1. A subgroup analysis of 96 grafts (52 with histidine-tryptophanketoglutarate/44 with University of Wisconsin) with pancreas graft cold ischemic time ≥12 hours was also performed. RESULTS: At mean follow-up of 75.2 ± 9.9 months, both groups demonstrated comparable short- and long-term patient survival. Overall, pancreas graft survival was slightly better in the histidine-tryptophan-ketoglutarate group (Kaplan-Meier analysis, log-rank P = .013). However, the subgroup analysis of grafts with cold ischemic time ≥12 hours showed slightly better pancreatic graft survival in the University of Wisconsin group, although not significantly (log-rank P = .95). Serum lipase and C-reactive protein levels at postoperative week 1 were higher in the histidinetryptophan-ketoglutarate group. Surgical complications were comparable. Multivariable Cox regression analysis identified neither solution as a risk factor affecting patient and graft survival. CONCLUSIONS: Although a direct comparison between histidine-tryptophan-ketoglutarate and University of Wisconsin showed better pancreas graft survival with histidine-tryptophan-ketoglutarate, the multivariable analysis showed that the perfusion solution does not significantly influence patient and graft survival. However, in the analysis of transplants with cold ischemic time ≥12 hours, pancreas graft survival was slightly better in the University of Wisconsin group, although not significantly.


Subject(s)
Histidine , Organ Preservation Solutions , Adenosine , Allopurinol/adverse effects , C-Reactive Protein , Cold Ischemia/adverse effects , Glucose/adverse effects , Glutathione , Humans , Insulin/adverse effects , Lipase , Organ Preservation Solutions/adverse effects , Pancreas , Raffinose/adverse effects , Retrospective Studies , Treatment Outcome , Tryptophan , Universities , Wisconsin
2.
J Surg Res ; 242: 157-165, 2019 10.
Article in English | MEDLINE | ID: mdl-31078900

ABSTRACT

BACKGROUND: Limited data exist that compare the predominant cardiac preservation solutions (CPSs). MATERIALS AND METHODS: The United Network for Organ Sharing database was retrospectively reviewed from January 1, 2004 to March 31, 2018, for donor hearts. Of 34,614 potential donors, 21,908 remained after applying the exclusion criteria. The CPS analyzed included saline, the University of Wisconsin (UW), cardioplegia, Celsior, and Custodiol. The primary endpoints were recipient survival and posttransplant rejection. Logistic and Cox models were used to quantify survival endpoints. RESULTS: Saline was used as the CPS in 2549 patients (12%), UW in 10,549 (48%), cardioplegia in 1307 (6%), Celsior in 5081 (23%), and Custodiol in 2422 (11%). Donor age ranged from 15 to 68 y (mean = 32.0 y, median = 30.0 y), and 71% were male. Adjusted survival probabilities of recipients whose donor hearts were procured with saline was 96% 30 d, 90% 1 y, UW: 97% 30 d, 92% 1 y, cardioplegia: 95% 30 d, 87% 1 y, Celsior: 96% 30 d, 90% 1 y, and Custodiol: 97% 30 d, 92% 1 y. When these comparisons were adjusted for donor age, sex, ethnicity, ischemic time, recipient age, sex, ethnicity, creatinine, ventricular assist device (VAD), length of stay, region and days on waiting list, cardioplegia solution was demonstrated to have a higher risk of death (30 d, 1 y, overall) and posttransplant rejection versus UW (odds ratio 1.70, P = 0.001; odds ratio 1.63, P < 0.001; hazard ratio 1.22, P < 0.001; hazard ratio 1.21, P < 0.001, respectively). CONCLUSIONS: Cardioplegia solutions for cardiac preservation are associated with a higher mortality in heart transplant recipients.


Subject(s)
Cardioplegic Solutions/adverse effects , Graft Rejection/epidemiology , Heart Failure/surgery , Organ Preservation Solutions/adverse effects , Organ Preservation/adverse effects , Adenosine/adverse effects , Adolescent , Adult , Aged , Allografts/drug effects , Allopurinol/adverse effects , Disaccharides/adverse effects , Electrolytes/adverse effects , Female , Follow-Up Studies , Glucose/adverse effects , Glutamates/adverse effects , Glutathione/adverse effects , Graft Rejection/etiology , Graft Rejection/prevention & control , Graft Survival/drug effects , Heart/drug effects , Heart Failure/mortality , Heart Transplantation/adverse effects , Histidine/adverse effects , Humans , Insulin/adverse effects , Male , Mannitol/adverse effects , Middle Aged , Organ Preservation/methods , Potassium Chloride/adverse effects , Procaine/adverse effects , Raffinose/adverse effects , Retrospective Studies , Saline Solution/adverse effects , Survival Analysis , Treatment Outcome , Young Adult
3.
Transplantation ; 102(11): 1870-1877, 2018 Nov.
Article in English | MEDLINE | ID: mdl-30130321

ABSTRACT

BACKGROUND: Both University of Wisconsin (UW) and histidine-tryptophan-ketoglutarate (HTK) solutions are currently used in the Eurotransplant region for preservation of liver allografts. Previous studies on their effect have led to a lot of discussion. This study aims to compare the effect of HTK and UW on graft survival. METHODS: First liver transplantations in recipients 18 years or older from January 1, 2007, until December 31, 2016, were included. Graft survival was compared for livers preserved with HTK and UW at 30 days, 1, 3, and 5 years. Multivariable analysis of risk factors was performed and outcome was adjusted for important confounders. RESULTS: Of all 10 628 first liver transplantations, 8176 (77%) and 2452 (23%) were performed with livers preserved with HTK and UW, respectively. Kaplan-Meier curves showed significant differences in graft survival between HTK and UW at 30 days (89% vs 93%, P=<0.001), 1 year (75% vs 82%, P=<0.001), 3 years (67% vs 72%, P<0.001), and at 5 years (60% vs 67%, P<0.001). No significant differences in outcome were observed in separate analyses of Germany or non-German countries. In multivariable analysis, UW was associated with a decreased risk of graft loss at 30 days (HR 0.772, P=0.002) and at 1 year (0.847 (0.757-0.947). When adjusted for risk factors, no differences in long term outcome could be detected. CONCLUSIONS: Because the use of preservation fluids is clustered geographically, differences in outcome by preservation fluids are strongly affected by regional differences in donor and recipient characteristics. When adjusted for risk factors, no differences in graft survival exist between transplantations performed with livers preserved with either HTK or UW.


Subject(s)
Graft Survival/drug effects , Liver Transplantation/methods , Organ Preservation Solutions/therapeutic use , Organ Preservation/methods , Adenosine/adverse effects , Adenosine/therapeutic use , Adult , Aged , Allopurinol/adverse effects , Allopurinol/therapeutic use , Europe , Female , Glucose/adverse effects , Glucose/therapeutic use , Glutathione/adverse effects , Glutathione/therapeutic use , Healthcare Disparities , Humans , Insulin/adverse effects , Insulin/therapeutic use , Liver Transplantation/adverse effects , Male , Mannitol/adverse effects , Mannitol/therapeutic use , Middle Aged , Organ Preservation/adverse effects , Organ Preservation Solutions/adverse effects , Potassium Chloride/adverse effects , Potassium Chloride/therapeutic use , Procaine/adverse effects , Procaine/therapeutic use , Raffinose/adverse effects , Raffinose/therapeutic use , Registries , Retrospective Studies , Risk Factors , Time Factors , Treatment Outcome
4.
J Pharmacol Exp Ther ; 366(1): 29-36, 2018 07.
Article in English | MEDLINE | ID: mdl-29739826

ABSTRACT

Intestinal preservation injury (IPI) and the resulting mucosa injury raise several serious challenges early after intestinal transplantation. The current clinical approach using only vascular perfusion allows the shortest preservation period among the abdominal organs. The experimental addition of luminal polyethylene glycol (PEG) solutions has been repeatedly suggested to alleviate preservation injury, improve graft quality, and prolong the preservation time. We investigated whether the molecular mass of PEG in solution influences the development of intestinal preservation injury. Small intestines of Sprague-Dawley rats were perfused with University of Wisconsin solution. Group 1 underwent vascular perfusion only (clinical control), group 2 received additional luminal PEG3350 Da, group 3 received luminal PEG10000 Da, and group 4 received luminal PEG20000 Da (n = 8/group). Tissue samples were obtained after 4, 8, and 14 hours. We studied the tissue damage (Chiu/Park score, Goblet cells, apoptosis, tight junctions), activation of c-Jun NH2-terminal kinase (JNK), and p38-mitogen-activated protein kinase (MAPK), and we performed Ussing chamber assessments. Mucosal morphologic and electrophysiologic parameters were significantly improved in the groups receiving luminal PEG. There was significantly less apoptotic activity in groups 2, 3, and 4. Both MAPKs revealed an activation peak after 4 hours with group 3 showing lesser p38-MAPK activation. PEG 20 kDa interfered with protein immunodetection. The results indicate that luminal solutions of PEG of medium and large molecular mass significantly delay the onset and development of IPI, providing further evidence that luminal interventions may allow for longer cold storage intervals of intestinal grafts.


Subject(s)
Intestine, Small/drug effects , Intestine, Small/injuries , Organ Preservation Solutions/adverse effects , Polyethylene Glycols/pharmacology , Adenosine/adverse effects , Allopurinol/adverse effects , Animals , Apoptosis/drug effects , Glutathione/adverse effects , Insulin/adverse effects , Intestine, Small/metabolism , Intestine, Small/pathology , JNK Mitogen-Activated Protein Kinases/metabolism , Male , Molecular Weight , Permeability/drug effects , Polyethylene Glycols/chemistry , Raffinose/adverse effects , Rats , Rats, Sprague-Dawley , Tight Junctions/drug effects , Tight Junctions/metabolism , p38 Mitogen-Activated Protein Kinases/metabolism
5.
Transplant Proc ; 50(2): 539-542, 2018 Mar.
Article in English | MEDLINE | ID: mdl-29579846

ABSTRACT

INTRODUCTION: Ischemia reperfusion injury (IRI) is the main cause of early allograft dysfunction (EAD) and subsequent primary allograft failure (PAF). OBJECTIVES: The purpose of this study is to compare IRI, EAD, and PAF in liver transplantation in a cohort of patients perfused with histidine-tryptophan-ketoglutarate (HTK) solution and University of Wisconsin (UW) solution versus HTK alone. METHODS: A randomized trial was performed to compare outcomes in liver recipients who underwent transplantation surgery in the University Regional Hospital of Malaga, Spain. Forty patients were randomized to two groups. Primary endpoints included IRI, EAD, PAF, re-intervention, acute cellular rejection, retransplantation, arterial complications, and biliary complications at postoperative day 90. RESULTS: Postoperative glutamic oxaloacetic transaminase (1869.15 ± 1559.75 UI/L vs. 953.15 ± 777.27 UI/L; P = .004) and glutamic pyruvic transaminase (1333.60 ± 1115.49 U/L vs. 721.70 ± 725.02 U/L; P = .023) were significantly higher in patients perfused with HTK alone. A clear tendency was observed in recipients perfused with HTK alone to present moderate to severe IRI (7 patients in the HTK + UW solution group vs. 15 patients in the HTK-alone solution group; P = .06), EAD (0 patients in the HTK + UW solution group vs. 0 patients in the HTK-alone solution group; P = .76), and PAF (3 patients in the HTK + UW solution group vs. 8 patients in the HTK-alone solution group; P = .15). CONCLUSIONS: Initial perfusion with HTK solution followed by UW solution in liver transplantation improves early liver function as compared to perfusion with HTK alone.


Subject(s)
Liver Transplantation/methods , Organ Preservation Solutions/administration & dosage , Perfusion/methods , Adenosine/administration & dosage , Adenosine/adverse effects , Adult , Alanine Transaminase/blood , Allopurinol/administration & dosage , Allopurinol/adverse effects , Aspartate Aminotransferases/blood , Cohort Studies , Drug Therapy, Combination , Female , Glucose/administration & dosage , Glucose/adverse effects , Glutathione/administration & dosage , Glutathione/adverse effects , Graft Rejection/chemically induced , Humans , Insulin/administration & dosage , Insulin/adverse effects , Liver , Male , Mannitol/administration & dosage , Mannitol/adverse effects , Middle Aged , Organ Preservation Solutions/adverse effects , Perfusion/adverse effects , Postoperative Period , Potassium Chloride/administration & dosage , Potassium Chloride/adverse effects , Procaine/administration & dosage , Procaine/adverse effects , Raffinose/administration & dosage , Raffinose/adverse effects , Reoperation , Reperfusion Injury/chemically induced , Spain , Treatment Outcome
6.
Transplantation ; 101(9): 2111-2114, 2017 09.
Article in English | MEDLINE | ID: mdl-28518062

ABSTRACT

BACKGROUND: Prograde flushing (PF) of living donor renal allografts with preservation solution via the renal artery or arteries is standard practice. PF may be difficult and potentially injurious to the donor kidney, especially in grafts with small or multiple arteries. In this report, we present our experience with retrograde flushing (RF) of 7 living donor kidneys via the renal vein. METHODS: Retrospective review of 7 consecutive living donor renal transplants performed using the RF technique was performed. The 7 preceding living donor renal transplants performed using the standard arterial PF technique served as a control group. RESULTS: All 7 recipients of RF kidneys experienced immediate graft function. At postoperative days 3 and 30, there was no difference in estimated glomerular filtration rate between the RF study group and PF controls. CONCLUSIONS: The RF technique is simple and safe, with results equivalent to the PF technique. The RF technique may be especially useful after recovering kidneys with small and/or multiple arteries.


Subject(s)
Kidney Transplantation/methods , Living Donors , Nephrectomy , Organ Preservation Solutions/administration & dosage , Renal Veins/surgery , Therapeutic Irrigation/methods , Adenosine/administration & dosage , Adenosine/adverse effects , Adult , Aged , Allopurinol/administration & dosage , Allopurinol/adverse effects , Female , Glomerular Filtration Rate , Glutathione/administration & dosage , Glutathione/adverse effects , Humans , Infusions, Intravenous , Insulin/administration & dosage , Insulin/adverse effects , Kidney Transplantation/adverse effects , Male , Middle Aged , Organ Preservation Solutions/adverse effects , Raffinose/administration & dosage , Raffinose/adverse effects , Recovery of Function , Retrospective Studies , Therapeutic Irrigation/adverse effects , Time Factors , Treatment Outcome
7.
Exp Clin Transplant ; 15(4): 432-436, 2017 Aug.
Article in English | MEDLINE | ID: mdl-26114393

ABSTRACT

OBJECTIVES: One of the main concerns in liver transplant is the prolonged ischemia time, which may lead to primary graft nonfunction or delayed function. N-acetylcysteine is known as a hepato-protective agent in different studies, which may improve human hepatocyte viability in steatotic donor livers. This study investigated whether N-acetylcysteine can decrease the rate of ischemia-reperfusion syndrome and improve short-term outcome in liver transplant recipients. MATERIALS AND METHODS: This was a double-blind, randomized, control clinical trial of 115 patients. Between April 2012 and January 2013, patients with orthotopic liver transplant were randomly divided into 2 groups; in 49 cases N-acetylcysteine was added to University of Wisconsin solution as the preservative liquid (experimental group), and in 66 cases standard University of Wisconsin solution was used (control group). We compared postreperfusion hypotension, inotrope requirement before and after portal reperfusion, intermittent arterial blood gas analysis and potassium measurement, pathological review of transplanted liver, in-hospital complications, morbidity, and mortality. RESULTS: There was no significant difference between the groups regarding time to hepatic artery reperfusion, hospital stay, vascular complications, inotrope requirement before and after portal declamping, and blood gas analysis. Hypotension after portal reperfusion was significantly more common in experimental group compared with control group (P = .005). Retransplant and in-hospital mortality were comparable between the groups. CONCLUSIONS: Preservation of the liver inside Univer-sity of Wisconsin solution plus N-acetylcysteine did not change the rate of ischemia reperfusion injury and short-term outcome in liver transplant recipients.


Subject(s)
Acetylcysteine/administration & dosage , Liver Transplantation/methods , Organ Preservation Solutions/administration & dosage , Perfusion/methods , Protective Agents/administration & dosage , Reperfusion Injury/prevention & control , Acetylcysteine/adverse effects , Adenosine/administration & dosage , Adenosine/adverse effects , Allopurinol/administration & dosage , Allopurinol/adverse effects , Cold Ischemia , Double-Blind Method , Female , Glutathione/administration & dosage , Glutathione/adverse effects , Hospital Mortality , Humans , Hypotension/etiology , Insulin/administration & dosage , Insulin/adverse effects , Iran , Length of Stay , Liver Transplantation/adverse effects , Liver Transplantation/mortality , Male , Middle Aged , Operative Time , Organ Preservation Solutions/adverse effects , Perfusion/adverse effects , Perfusion/mortality , Protective Agents/adverse effects , Raffinose/administration & dosage , Raffinose/adverse effects , Reperfusion Injury/diagnosis , Reperfusion Injury/etiology , Reperfusion Injury/mortality , Risk Factors , Time Factors , Treatment Outcome , Warm Ischemia
8.
Int J Food Sci Nutr ; 67(4): 383-90, 2016 Jun.
Article in English | MEDLINE | ID: mdl-27002546

ABSTRACT

Dietary restriction of fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAPs) is an effective management approach for functional bowel disorders; however, its application is limited by the paucity of food composition data available for ethnic minority groups. The aim was to identify and measure the FODMAP content of these commonly consumed foods. According to their perceived importance to clinical practise, the top 20 ranked foods underwent FODMAP analysis using validated analytical techniques (total fructans, Megazyme hexokinase (HK) assay; all others, high-performance liquid chromatography (HPLC) with evaporative light scattering detectors). Of the 20 foods analysed, five were identified as significant sources of at least one FODMAP. Fructans and galacto-oligosaccharides were the major FODMAPs in these foods, including channa dal (0.13 g/100 g; 0.36 g/100 g), fenugreek seeds (1.11 g/100 g; 1.27 g/100 g), guava (0.41 g/100 g; not detected), karela (not detected; 1.12 g/100 g) and tamarind (2.35 g/100 g; 0.02 g/100 g). Broadening the availability of FODMAP composition data will increase the cultural application of low FODMAP dietary advice.


Subject(s)
Diet , Disaccharides/analysis , Food Analysis , Minority Groups , Monosaccharides/analysis , Oligosaccharides/analysis , Sugar Alcohols/analysis , Asian People , Black People , Caribbean Region/ethnology , Culturally Competent Care , Diet/ethnology , Diet Surveys , Diet, Carbohydrate-Restricted/ethnology , Disaccharides/adverse effects , Disaccharides/metabolism , Fermentation , Focus Groups , Fructans/adverse effects , Fructans/analysis , Fructans/metabolism , Humans , Internet , Monosaccharides/adverse effects , Monosaccharides/metabolism , Nutritionists , Oligosaccharides/adverse effects , Oligosaccharides/metabolism , Raffinose/adverse effects , Raffinose/analysis , Raffinose/metabolism , Sugar Alcohols/adverse effects , Sugar Alcohols/metabolism , United Kingdom
9.
J Thorac Cardiovasc Surg ; 148(3): 1123-30; discussion 1130, 2014 Sep.
Article in English | MEDLINE | ID: mdl-25129607

ABSTRACT

OBJECTIVE: To investigate the resuscitation potential and contractile function in adult human donation after cardiac death (DCD) hearts by ex vivo perfusion. METHODS: With institutional review board approval and under the DCD protocol at the University of Wisconsin (UW) Organ Procurement Organization, 5 brain dead (BD) and 5 DCD donor hearts were evaluated. All BD hearts were declined for clinical transplantation because of coronary artery disease, advanced age, or social history. All hearts were preserved by flushing and cold storage with UW solution. By using our ex vivo perfusion system, the left ventricular end systolic pressure-volume relationship (LV-ESPVR) was assessed for 2 hours of oxygenated blood reperfusion. RESULTS: All BD (n = 5) and 4 DCD hearts were successfully resuscitated. One DCD heart was unable to be resuscitated due to prolonged warm ischemic time (WIT; 174 minutes). Mean WIT for resuscitated DCD hearts (from extubation to flushing with cold UW solution) was 34 ± 3 minutes (range, 26 to 40 minutes); mean cold ischemic time for BD donors was 211 ± 31 minutes compared with 177 ± 64 minutes for DCD donors. The calculated LV-ESPVRs for BD hearts after 1 and 2 hours of reperfusion were 6.9 ± 0.7 and 5.7 ± 1.0 mm Hg/mL, respectively; LV-ESPVRs for DCD hearts after 1 and 2 hours of reperfusion were 5.6 ± 1.5 (P = .45) and 3.0 ± 0.7 mm Hg/mL (P = .07), respectively. CONCLUSIONS: We successfully resuscitated and measured ex vivo cardiac function in human DCD and BD donor hearts. Resuscitation potential in DCD hearts was achieved when the WIT was less than 40 minutes. Contractile performance in DCD hearts tended to be lower compared with BD hearts. Further investigation with longer reperfusion periods seems warranted.


Subject(s)
Brain Death , Heart Diseases/mortality , Heart Transplantation , Organ Preservation Solutions/pharmacology , Perfusion/methods , Tissue Donors/supply & distribution , Tissue and Organ Harvesting/methods , Adenosine/adverse effects , Adenosine/pharmacology , Adult , Allopurinol/adverse effects , Allopurinol/pharmacology , Cold Ischemia , Female , Glutathione/adverse effects , Glutathione/pharmacology , Humans , Insulin/adverse effects , Insulin/pharmacology , Male , Middle Aged , Myocardial Contraction , Organ Preservation Solutions/adverse effects , Perfusion/adverse effects , Raffinose/adverse effects , Raffinose/pharmacology , Time Factors , Tissue and Organ Harvesting/adverse effects , Ventricular Function, Left , Ventricular Pressure , Warm Ischemia , Wisconsin
10.
Can J Diet Pract Res ; 75(4): 218-21, 2014 Dec.
Article in English | MEDLINE | ID: mdl-26067078

ABSTRACT

PURPOSE: Consumption of pulses is recommended to improve diet quality and decrease the risk of chronic disease. However, their constituent α-galactosides, including raffinose, are commonly thought to contribute to unpleasant gastrointestinal symptoms. METHODS: Using a random crossover design, healthy adults (n = 12) received control foods, control foods with 5 g raffinose, and foods with 200 g of canned chickpea (11 g fibre per day), each for three weeks following a 3-day diet rotation. Gastrointestinal symptoms (rating 0 = none to 3 = severe), compliance, and stool frequency were recorded daily. RESULTS: No change in daily stool frequency (mean ± SD) was found with chickpea (1.7 ± 0.3) or raffinose (1.7 ± 0.4) compared with control (1.5 ± 0.3). Reported flatulence (mean ± SD) was rated higher with chickpea (1.0 ± 0.2, P < 0.001) and raffinose (0.7 ± 0.2, P < 0.001) compared with control (0.4 ± 0.1). Although bloating was infrequent, ratings were higher with chickpea (0.2 ± 0.1, P < 0.001) and raffinose (0.3 ± 0.1, P < 0.001) compared with control (0.0). No differences were found for diarrhea or abdominal pain. CONCLUSIONS: As gastrointestinal symptoms were mild for most participants, canned chickpea may be a feasible way of increasing pulse intake and improving overall diet quality.


Subject(s)
Cicer/adverse effects , Food, Preserved/adverse effects , Functional Food/adverse effects , Gastric Mucosa/physiopathology , Gastroenteritis/etiology , Gastrointestinal Tract/physiopathology , Seeds/adverse effects , Adolescent , Adult , Cross-Over Studies , Dietary Fiber/adverse effects , Female , Flatulence/etiology , Gastric Mucosa/immunology , Gastroenteritis/immunology , Gastroenteritis/physiopathology , Gastrointestinal Tract/immunology , Humans , Male , Patient Compliance , Raffinose/adverse effects , Severity of Illness Index , Single-Blind Method , Young Adult
11.
Ann Transplant ; 18: 146-52, 2013 Mar 27.
Article in English | MEDLINE | ID: mdl-23792514

ABSTRACT

BACKGROUND: The aim of this study was to compare 2 preservation solutions in kidney transplant recipients in the same center during the same period since initiation of the use of High Na+; low K+ solution (Celsior). MATERIAL AND METHODS: From January 1999 to April 2011, 610 consecutive renal transplantations were done in our department with deceased donor kidneys. Data were collected prospectively. Organ procurement was performed in our center for 305 kidneys. We washed and preserved 409 kidneys in UW, and 201 in Celsior solution. RESULTS: Donors criteria were worse in the Celsior group for age, male sex, creatinemia, and cold ischemia. Populations of recipients were comparable. There were no differences at 1 and 12 months in creatinine levels (p=0.9 and 0.8, respectively) and in number of delayed graft functions (DGF) (p=0.8 and relative risk =0.9) between groups. There were no differences in post-transplantation outcomes for all variables. At 5 years, graft survival was 90.4% for UW and 93.5% for Celsior (p=0.44). CONCLUSIONS: Our retrospective study did not succeed in demonstrating superiority of a High Na+; low K+ solution compared to a UW type reference solution. Celsior has the same effectiveness as UW during kidney cold storage.


Subject(s)
Kidney Transplantation/methods , Organ Preservation Solutions , Adenosine/adverse effects , Adolescent , Adult , Aged , Allopurinol/adverse effects , Delayed Graft Function/etiology , Disaccharides/adverse effects , Electrolytes/adverse effects , Female , France/epidemiology , Glutamates/adverse effects , Glutathione/adverse effects , Graft Survival , Histidine/adverse effects , Humans , Insulin/adverse effects , Kaplan-Meier Estimate , Kidney Transplantation/adverse effects , Kidney Transplantation/mortality , Male , Mannitol/adverse effects , Middle Aged , Organ Preservation Solutions/adverse effects , Prospective Studies , Raffinose/adverse effects , Time Factors , Treatment Outcome , Young Adult
12.
Transplant Proc ; 44(2): 366-8, 2012 Mar.
Article in English | MEDLINE | ID: mdl-22410018

ABSTRACT

BACKGROUND: The potassium content of University of Wisconsin solution (UW) is 125 mEq/L and that of histidine-tryptophan-ketoglutarate solution (HTK) only 9 mEq/L. The aim of the present study was to analyze their effects to change potassium levels on reperfusion among patients undergoing living-donor liver transplantation. METHODS: Anesthesia records of adult living-donor liver transplant patients were reviewed retrospectively. Patients received liver graft preserved in UW were grouped in group I (GI) and HTK in group II (GII). The potassium levels in the anheptic phase were compared with those 5 minutes after reperfusion using paired Student t tests. P values of <.05 were regarded to be significant. RESULTS: Eighty-five GI patients showed the potassium significantly decreased from 3.76±0.70 to 3.60±0.74, whereas the change among 355 GII patients was almost unremarkable: 4.00±0.57 to 3.96±0.06 mEq/L. CONCLUSIONS: Although UW contains a higher potassium content, it seems to have no negative impact on changes in serum potassium levels; in contrast it decreased the potassium level significantly at 5 minutes after reperfusion. Both preservation solutions maintain the patients' potassium levels within the normal range.


Subject(s)
Hepatectomy , Liver Transplantation , Living Donors , Organ Preservation Solutions/therapeutic use , Organ Preservation/methods , Potassium/blood , Adenosine/adverse effects , Adenosine/therapeutic use , Adult , Allopurinol/adverse effects , Allopurinol/therapeutic use , Biomarkers/blood , Glucose/adverse effects , Glucose/therapeutic use , Glutathione/adverse effects , Glutathione/therapeutic use , Hepatectomy/adverse effects , Humans , Hyperkalemia/blood , Hyperkalemia/etiology , Insulin/adverse effects , Insulin/therapeutic use , Liver Transplantation/adverse effects , Mannitol/adverse effects , Mannitol/therapeutic use , Middle Aged , Organ Preservation/adverse effects , Organ Preservation Solutions/adverse effects , Potassium Chloride/adverse effects , Potassium Chloride/therapeutic use , Procaine/adverse effects , Procaine/therapeutic use , Raffinose/adverse effects , Raffinose/therapeutic use , Reference Values , Reperfusion , Retrospective Studies , Risk Factors , Taiwan , Time Factors , Treatment Outcome
13.
J Reprod Dev ; 57(1): 92-8, 2011 Feb.
Article in English | MEDLINE | ID: mdl-21079376

ABSTRACT

Although procedures for in vitro fertilization with cryopreserved sperm have been published there is a lack of data indicating that the cryoprotectant and cryopreservation procedures used for those procedures were optimal. To redress this, fertilization rate of eggs exposed to sperm in vitro was used as the outcome in the optimization of raffinose concentration in the cryoprotectant (raffinose in water), volume of cryoprotectant, and freezing conditions for C57BL/6J mouse sperm. Sperm were frozen in a cylindrical Dewar with an internal diameter and height of 14.0 cm and 36.0 cm respectively. The optimal concentration of raffinose was 23-24% (510-540 mOsm/kg). The optimal volume of cryoprotectant used to prepare the sperm suspension from a single mouse was 180-400 µl, and sperm proved most fertile when frozen 13-25 mm above liquid nitrogen. Raffinose in the fertilization medium did not inhibit fertilization. Fertilized eggs transferred to oviducts of recipient mice developed into viable offspring.


Subject(s)
Cryopreservation/methods , Fertilization , Semen Preservation/veterinary , Spermatozoa/drug effects , Abnormalities, Drug-Induced/prevention & control , Animals , Cryoprotective Agents/adverse effects , Embryo Transfer , Female , Fertilization/drug effects , Fertilization in Vitro , Male , Mice , Mice, Inbred C57BL , Mice, Inbred CBA , Osmolar Concentration , Pregnancy , Pregnancy Outcome , Pregnancy Rate , Raffinose/adverse effects , Semen Preservation/methods , Spermatozoa/physiology
14.
Prog Transplant ; 20(3): 256-61, 2010 Sep.
Article in English | MEDLINE | ID: mdl-20929110

ABSTRACT

BACKGROUND: The greatest hemodynamic instability during orthotopic liver transplantation occurs at graft reperfusion. Many factors have been implicated. PURPOSE: To compare hemodynamic changes after reperfusion in grafted livers preserved with histidine-tryptophan-ketoglutarate (HTK) solution versus grafted livers preserved with University of Wisconsin (UW) solution. METHODS: In this prospective study, we randomly divided 89 patients who underwent deceased donor liver transplantation into 2 groups: the UW group and the HTK group. The HTK group was further divided into 2 subgroups: flushed and not flushed before reperfusion. The patients were monitored with hemodynamic and metabolic parameters at 3 times: after the skin incision, 5 minutes before reperfusion, and 5 minutes after reperfusion. RESULTS: Hemodynamic parameters in the UW group had not changed significantly at 5 minutes before reperfusion or 5 minutes after reperfusion (P = .45), and the incidence of hypotension after reperfusion in the UW group was 20%. In both HTK groups, the mean arterial pressure 5 minutes after reperfusion was significantly lower than at 5 minutes before reperfusion (P = .002); the incidence of hypotension after reperfusion in the nonflushed HTK group was 83.3% and in the flushed HTK group, 65.5%. CONCLUSIONS: The incidence of hypotension after reperfusion is greater if HTK solution rather than UW solution is used. Flushing of grafted livers preserved with HTK solution might eliminate some vasoactive substances found in HTK solution.


Subject(s)
Hypotension/chemically induced , Liver Transplantation , Organ Preservation Solutions/adverse effects , Organ Preservation , Adenosine/adverse effects , Adult , Allopurinol/adverse effects , Blood Gas Analysis , Female , Glucose/adverse effects , Glutathione/adverse effects , Hemodynamics/drug effects , Humans , Hypotension/epidemiology , Hypotension/metabolism , Hypotension/physiopathology , Incidence , Insulin/adverse effects , Liver Transplantation/methods , Male , Mannitol/adverse effects , Organ Preservation/adverse effects , Organ Preservation/methods , Potassium Chloride/adverse effects , Procaine/adverse effects , Prospective Studies , Raffinose/adverse effects , Reperfusion/methods , Therapeutic Irrigation
15.
Transplant Proc ; 42(1): 159-61, 2010.
Article in English | MEDLINE | ID: mdl-20172305

ABSTRACT

Institute Georges Lopez preservation solution (IGL-1) has been demonstrated to be useful for fatty liver preservation. The mechanisms responsible for this effective graft protection against ischemia-reperfusion injury are pivotal actions on generation of nitric oxide a diffusible molecule with vasodilator properties, that facilitates the up-regulation of other well-known cytoprotective genes, such as hypoxia-inducible factor-1 alpha (HIF-1alpha) and heme-oxygenase 1 (HO-1). During normoxic reperfusion, the presence of nitric oxide permits HIF-1alpha accumulation to inhibit prolyl-hydoxylases, thus promoting an additional overexpression of the HO-1 in steatotic and nonsteatotic graft livers preserved in IGL-1.


Subject(s)
Fatty Liver/metabolism , Liver Transplantation/pathology , Organ Preservation Solutions , Organ Preservation/methods , Adenosine/adverse effects , Allopurinol/adverse effects , Erythrocyte Aggregation/drug effects , Fatty Liver/pathology , Fatty Liver/surgery , Glutathione/adverse effects , Heme Oxygenase-1/genetics , Humans , Hypoxia-Inducible Factor 1, alpha Subunit/genetics , Insulin/adverse effects , Nitric Oxide Synthase/metabolism , Organ Preservation Solutions/adverse effects , Patient Selection , Raffinose/adverse effects , Up-Regulation
16.
Transpl Int ; 23(1): 14-22, 2010 Jan.
Article in English | MEDLINE | ID: mdl-19691661

ABSTRACT

Ischemic-type biliary lesions (ITBL) account for a major part of patients' morbidity and mortality after orthotopic liver transplantation (OLT). The exact origin of this type of biliary complication remains unknown. This study retrospectively evaluated 1843 patients. Patients with primary sclerosing cholangitis were excluded from this study. The diagnosis of ITBL was established only when all other causes of destruction of the biliary tree were ruled out. Donor age (P = 0.028) and cold ischemic time (CIT) (P = 0.002) were found to be significant risk factors for the development of ITBL. Organs that were perfused with University of Wisconsin (UW) solution developed ITBL significantly more often than Histidine-Tryptophan-Ketoglutarate (HTK)-perfused organs (P = 0.036). The same applied to organs harvested externally and shipped to our center versus those that were procured locally by our harvest teams (P < 0.001). Pressure perfusion via the hepatic artery significantly reduced the risk of ITBL (P = 0.001). The only recipient factor that showed a significant influence was Child-Pugh score status C (P = 0.021). Immunologic factors had no significant impact on ITBL. The clinical consequences of this study for our institution have been the strict limitation of CIT to <10 h and the exclusive use of HTK solution. We further advocate that all organ procurement teams perform pressure perfusion on harvested organs.


Subject(s)
Biliary Tract Diseases/epidemiology , Cold Ischemia/adverse effects , Liver Transplantation/adverse effects , Adenosine/adverse effects , Adult , Allopurinol/adverse effects , Berlin/epidemiology , Biliary Tract Diseases/etiology , Female , Glucose/therapeutic use , Glutathione/adverse effects , Humans , Incidence , Insulin/adverse effects , Ischemia/epidemiology , Ischemia/etiology , Male , Mannitol/therapeutic use , Middle Aged , Organ Preservation Solutions/adverse effects , Perfusion/adverse effects , Perfusion/methods , Potassium Chloride/therapeutic use , Pressure , Procaine/therapeutic use , Raffinose/adverse effects , Retrospective Studies , Risk Factors , Tissue Donors , Tissue and Organ Harvesting/methods , Tissue and Organ Harvesting/standards
17.
Prog Transplant ; 18(3): 166-71; quiz 172, 2008 Sep.
Article in English | MEDLINE | ID: mdl-18831481

ABSTRACT

OBJECTIVE: To compare University of Wisconsin solution (Viaspan), the universal standard for organ preservation, with histidine-tryptophan-ketoglutarate solution. An analysis of each solution, in reference to clinical trials with specific organs, is presented and assessed to find the efficacy of each in a clinical environment. Also to view each solution from an economical standpoint, and in the end develop an overall understanding of the key similarities and differences between each solution in order to assess appropriate use of each in a clinical setting. DATA SOURCES: A literature search was conducted by using PubMed, MEDLINE, BIOSIS, Embase, and other online data bases to find the most recent studies of University of Wisconsin and histidine-tryptophan-ketoglutarate solutions. Search terms included University of Wisconsin solution, histidine-tryptophan-ketoglutarate, preservation solution, cost analysis, biliary complication, and other related subjects. STUDY SELECTION: Previous research was selected from the literature search to provide basic information on the 2 solutions and also to provide clinical examples of each solution and the efficacy of each with specific organs. DATA SYNTHESIS: Information and published articles on the 2 solutions were gathered for descriptive and comparative purposes. CONCLUSIONS: The 2 solutions appear equally effective in organ preservation. Each solution has its own organ-specific qualities, and each has different complications. The studies reviewed here indicate that the differences are minor and thus suggest that the 2 solutions are equally acceptable for clinical use. Of the 2 solutions, histidine-tryptophan-ketoglutarate costs less than University of Wisconsin solution.


Subject(s)
Organ Preservation Solutions , Adenosine/adverse effects , Adenosine/economics , Adenosine/pharmacology , Allopurinol/adverse effects , Allopurinol/economics , Allopurinol/pharmacology , Cost-Benefit Analysis , Glucose/adverse effects , Glucose/economics , Glucose/pharmacology , Glutathione/adverse effects , Glutathione/economics , Glutathione/pharmacology , Health Care Costs , Humans , Insulin/adverse effects , Insulin/economics , Insulin/pharmacology , Mannitol/adverse effects , Mannitol/economics , Mannitol/pharmacology , Organ Preservation Solutions/adverse effects , Organ Preservation Solutions/economics , Organ Preservation Solutions/pharmacology , Postoperative Complications , Potassium Chloride/adverse effects , Potassium Chloride/economics , Potassium Chloride/pharmacology , Procaine/adverse effects , Procaine/economics , Procaine/pharmacology , Quality of Life , Raffinose/adverse effects , Raffinose/economics , Raffinose/pharmacology
18.
JAMA ; 299(19): 2304-12, 2008 May 21.
Article in English | MEDLINE | ID: mdl-18443023

ABSTRACT

CONTEXT: Hemoglobin-based blood substitutes (HBBSs) are infusible oxygen-carrying liquids that have long shelf lives, have no need for refrigeration or cross-matching, and are ideal for treating hemorrhagic shock in remote settings. Some trials of HBBSs during the last decade have reported increased risks without clinical benefit. OBJECTIVE: To assess the safety of HBBSs in surgical, stroke, and trauma patients. DATA SOURCES: PubMed, EMBASE, and Cochrane Library searches for articles using hemoglobin and blood substitutes from 1980 through March 25, 2008; reviews of Food and Drug Administration (FDA) advisory committee meeting materials; and Internet searches for company press releases. STUDY SELECTION: Randomized controlled trials including patients aged 19 years and older receiving HBBSs therapeutically. The database searches yielded 70 trials of which 13 met these criteria; in addition, data from 2 other trials were reported in 2 press releases, and additional data were included in 1 relevant FDA review. DATA EXTRACTION: Data on death and myocardial infarction (MI) as outcome variables. RESULTS: Sixteen trials involving 5 different products and 3711 patients in varied patient populations were identified. A test for heterogeneity of the results of these trials was not significant for either mortality or MI (for both, I2 = 0%, P > or = .60), and data were combined using a fixed-effects model. Overall, there was a statistically significant increase in the risk of death (164 deaths in the HBBS-treated groups and 123 deaths in the control groups; relative risk [RR], 1.30; 95% confidence interval [CI], 1.05-1.61) and risk of MI (59 MIs in the HBBS-treated groups and 16 MIs in the control groups; RR, 2.71; 95% CI, 1.67-4.40) with these HBBSs. Subgroup analysis of these trials indicated the increased risk was not restricted to a particular HBBS or clinical indication. CONCLUSION: Based on the available data, use of HBBSs is associated with a significantly increased risk of death and MI.


Subject(s)
Blood Substitutes/adverse effects , Hemoglobins , Hemoglobins/adverse effects , Humans , Mortality , Myocardial Infarction/epidemiology , Raffinose/adverse effects , Raffinose/analogs & derivatives , Risk
19.
Hepatobiliary Pancreat Dis Int ; 5(4): 490-4, 2006 Nov.
Article in English | MEDLINE | ID: mdl-17085330

ABSTRACT

BACKGROUND: A safe and effective preservation solution is a precondition for liver transplantation, which is accepted as the radical treatment for patients with end-stage liver disease. The increasing use of marginal donors and non-heart beating donors as well as the establishment of a national organ allocation network call for better preservation. New preservation solutions like histidine-tryptophan-ketoglutarate (HTK) solution and Celsior solution have been introduced to liver preservation, and protective gene intervention and other modifications have also been investigated. In this article, we review recent advances in liver preservation solutions. DATA SOURCES: An English-language literature search was conducted using MEDLINE (1990-2005) on liver preservation solution, biliary complication, protective gene and other related subjects. RESULTS: Although the high viscosity of the University of Wisconsin (UW) solution proved harmful to the hepatic microcirculation, three solutions showed equivalent preservation effects. When the cold ischemia time was short, there were no significant differences among the three solutions in the incidence of biliary complications. So far, modifications of preservation solutions have achieved great success. Several types of protective genes like A20, Bcl-2, Bcl-X(L) and HO-1 were reported to have definite liver protective effects. The addition of other substrates like TNF-alpha antibody, tacrolimus (FK506) and fructose-1,6-bisphosphate (FBP) can also improve the preservation effect. However, addition of insulin to UW solution is harmful to the graft. CONCLUSIONS: In centers with highly-developed transplantation techniques, HTK and Celsior solutions are acceptable in liver preservation. Protective gene modification and addition of substrates like TNF-alpha antibody, FK506 and FBP are prominent approaches to improve liver preservation.


Subject(s)
Liver , Organ Preservation Solutions , Adenosine/adverse effects , Allopurinol/adverse effects , Animals , Antibodies , Bile Duct Diseases/etiology , Disaccharides , Electrolytes , Fructosediphosphates , Glucose/adverse effects , Glutamates , Glutathione/adverse effects , Histidine , Humans , Insulin/adverse effects , Ischemia/etiology , Liver/blood supply , Mannitol/adverse effects , Microcirculation , Organ Preservation Solutions/adverse effects , Potassium Chloride/adverse effects , Procaine/adverse effects , Raffinose/adverse effects , Tacrolimus , Transformation, Genetic , Tumor Necrosis Factor-alpha/immunology
20.
Transplant Proc ; 37(6): 2456-8, 2005.
Article in English | MEDLINE | ID: mdl-16182707

ABSTRACT

BACKGROUND: The hydroxyethyl starch (HES) contained in University of Wisconsin (UW) solution causes erythrocyte aggregation. The effect of UW on red blood cell (RBC) deformability is still unclear. HES-free preservation solutions, Celsior (CS) and Custodiol (CU) are available. In this study we evaluated whether they really showed a reduced aggregating and stiffening effect on RBCs when compared with UW. We was also evaluated the effect of these solutions on cellular membranes by measuring acetylcholinesterase (AChE), which is a marker of RBC membrane integrity. METHODS: The determination of RBC aggregation and deformability was performed by a laser-assisted optical rotation cell analyzer (LORCA). AChE measurement was performed with a spectrophotometric technique. RESULTS: The mean RBC aggregation index (AI) measured in pure blood control samples was 28.00 +/- 0.73%. The AI measured samples containing UW was 38.82 +/- 1.58%. In samples with CS, it was 13.307 +/- 0.64% and in samples with CU the mean AI was 12.47 +/- 0.42%. Also the RBC aggregating time was quicker in presence of UW compared with controls. AChE concentration in blood was 3.043 +/- 0.4 nmol. CS and UW did not produce any significant change; a significant reduction was found when CU was added to blood, namely 1.975 +/- 0.1 nmol (P < .05). The use of UW or CS or CU did not result in any significant change in RBC deformability. DISCUSSION: CS and CU solutions do not aggregate erythrocytes, whereas Wisconsin does massively. CU causes an alteration of RBC cellular membrane as demonstrated by depletion of AChE.


Subject(s)
Erythrocyte Aggregation/drug effects , Erythrocyte Deformability/drug effects , Hemorheology/drug effects , Hydroxyethyl Starch Derivatives/pharmacology , Organ Preservation Solutions/adverse effects , Acetylcholinesterase/blood , Adenosine/adverse effects , Allopurinol/adverse effects , Disaccharides/pharmacology , Electrolytes/pharmacology , Glucose/pharmacology , Glutamates/pharmacology , Glutathione/adverse effects , Glutathione/pharmacology , Histidine/pharmacology , Humans , Insulin/adverse effects , Mannitol/pharmacology , Potassium Chloride/pharmacology , Procaine/pharmacology , Raffinose/adverse effects , Time Factors
SELECTION OF CITATIONS
SEARCH DETAIL
...